Company: AIP
Filing Date: 2025-11-04
Form Type: 10-Q
Source: 0001628280-25-048977
Chunk: 273

Company: Arteris, Inc.
Filing Date: 2025-11-04
Form: 10-Q
Item: Part I, Item 8
Chunk 273
---
 and development. We expect to maintain this full valuation allowance until it becomes more likely than not that the deferred tax assets will be realized.

26

Results of Operations

The following table summarizes our GAAP results of operations for the periods presented. The results below are not necessarily indicative of results to be expected for future periods. 

Three Months EndedNine Months EndedSeptember 30,September 30,2025202420252024(in thousands)Total revenue$17,408 $14,713 $50,442 $42,235 Cost of revenue (1)1,766 1,461 5,034 4,387 Gross profit15,642 13,252 45,408 37,848 Operating expenses:Research and development (1)12,648 11,923 36,681 33,475 Sales and marketing (1)6,850 4,962 19,714 15,431 General and administrative (1)4,858 4,286 13,683 13,436 Total operating expenses24,356 21,171 70,078 62,342 Loss from operations(8,714)(7,919)(24,670)(24,494)Interest expense(49)(55)(139)(199)Other income (expense), net636 775 2,140 2,576 Loss before income taxes and loss from equity method investment(8,127)(7,199)(22,669)(22,117)Loss from equity method investment, net of tax484 580 2,079 2,064 Provision for (benefit from) income taxes380 (92)1,494 1,253 Net loss$(8,991)$(7,687)$(26,242)$(25,434)

(1)Includes stock-based compensation expense as follows: 

Three Months EndedNine Months EndedSeptember 30,September 30,2025202420252024(in thousands)Cost of revenue$228 $221 $665 $596 Research and development2,095 2,154 5,994 5,550 Sales and marketing1,335 850 3,352 2,230 General and administrative1,298 1,165 3,754 3,431 Total stock-based compensation$4,956 $4,390 $13,765 $11,807 

27